Insights on the RNA Sequencing Global Market to 2026 - Demand for RNA Sequencing Over Traditional Technologies is Driving Growth - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 20, 2021--
The “RNA Sequencing Market - Forecasts from 2021 to 2026” report has been added to ResearchAndMarkets.com’s offering.
The global RNA sequencing market is projected to grow at a CAGR of 13.12% to reach US$6.264 billion by 2026, from US$2.643 billion in 2019.
The global demand for RNA sequencing over traditional technologies has proven to be the driving factor of industry growth. The RNA sequencing has higher sensitivity for genes expressed either at low or very high levels and a higher dynamic range of expression levels over which transcripts can be detected (>8000-fold range). Also, it provides insight into the transcriptome of a cell compared to previous conventional technologies and recent advances in the RNA-Seq workflow, from sample preparation to library construction to data analysis.
Also, the effectiveness of RNA sequencing in the current COVID-19 situation has led to many top industries adopting these technologies and hence leading to its growth. Its effectiveness again the treatment of many diseases such as cancer has improved the overall healthcare system.
The government and private sectors of developing countries have invested in their research and development sectors and in RNA sequencing programs to get a deep knowledge between genetics and diseases. Many such government organizations have taken an active part in the sequencing program to get better ways for the treatment of cancer and other diseases. Due to this large support, several new entrants have entered the market as many RNA sequencing projects have been introduced which leads to the overall growth of this industry and gives growth opportunities to key players in the industry
Less Cost of Sequencing and effectiveness in the treatment of cancer
The reduction in the cost of genome sequencing has led to the widespread adoption of these techniques thus positively impacting the adoption of RNA sequencing product lines. In addition to this, significant funding had been offered for technological advancements, including RNA sequencing, by government organizations. RNA sequencing also facilitates the identification of differentially expressed genes, had enabled several researchers to efficiently identify up and down-regulated genes that are associated with different cancers.
Lack of skill power and expenditure on Research and Development Programs
The expenditure on research and development in growing economies is mainly dependent on funding provided by external sources. Although governments and private bodies try to provide funds for the research programs, many research firms and academic institutes are facing budget problems and are not able to afford advanced and premium-priced equipment and technologies which further leads to an effect on the growth of these industries and their expansion in developing nations.
The RNA-based mappings depend on cDNA synthesis which poses a challenge in short-lived transcripts such as primary microRNAs, the efficiency of which is dependent on RNA sequence and structure Also, the lack of skilled professional in this industry are less in number which further hinders the growth of this industry. Due to this, the interpretation of complex data takes time and researchers face difficulties leading to slow growth in the industry.
Impact of COVID-19 on the RNA sequencing market
The COVID-19 pandemic has had a great impact on the world as a whole and has led to economic breakdown and loss of life. It has caused a highly transmissible and ongoing pandemic worldwide. Due to its rapid development, global RNA sequencing plays a vital role in many aspects. The impact of COVID-19 seems to be positive on the global RNA sequencing market. It has been primarily attributed to the major drivers in this market, such as increases in adoption of personalized medicines, therapeutic response research, external funding for executive Research & Development. However, the accuracy standardization concerns in testing and lack of skilled technical personal are some of the key factors limiting the growth of the market.
In addition to this, the global RNA sequencing technology is playing a vital role against COVID-19 alone with its mutations, transmission, and genetics research. Also, COVID-19 has highlighted the need for genomic sequencing tools from initial detection of the emerging virus to diagnostic. These all factors are promoting the developments and investments are being done by big pharma and technology players to support these new diagnostic test methods
- Ion Semiconductor Sequencing
- Single-Molecule Real-Time (SMRT) Sequencing
- Nanopore Sequencing
- Sequencing By Synthesis (SBS)
- Small RNA Sequencing
- Expression Profiling Analysis
- De Novo Transcriptome Assembly
- Variant Calling and Transcriptome Epigenetics
- Research Centers
- Biotechnology Labs
- Healthcare Centers
- North America
- South America
- Middle East and Africa
- Saudi Arabia
- Asia Pacific
- Roche Holding AG
- Agilent Technologies
- Illumina, Inc.
- Thermo Fisher Scientific
- Macrogen, Inc.
- Beijing Genomics Institute
- GATC Biotech AG
- Pacific Biosciences of California, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/qwzy7v
View source version on businesswire.com:https://www.businesswire.com/news/home/20211220005703/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH GENERAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 12/20/2021 12:29 PM/DISC: 12/20/2021 12:29 PM